Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?

Study Overview
=================
Brief Summary
-----------------
Atrial fibrillation (AF) is a rhythmic cardiac activity disorder disturbing hemodynamic blood flow. It is a public health problem with 600,000 to 1 million people involved in France which 2/3 are aged over 75 years. a FA untreated exposes the patient to a significant risk of embolism responsible for a rate stroke (stroke) ischemic estimated at 85%. The anticoagulant standard treatment helps prevent the occurrence of this complication. However, oral anticoagulation also exposes patients to an increased risk of bleeding. The bleeding risk can be assessed using scales: several being proposed (HEMORR2HAGES, HAS-BLED, ATRIA and scores Shireman and Charlson ...). moreover, in geriatric hospital care, every patient has a standardized geriatric assessment to assess and quantify functional capacity, autonomy, cognitive abilities, nutritional status, psychological state and its environment social. Thus, the objective of the investigators study was to determine the frequency of each item of each bleeding risk assessment score and geriatric assessment in patients 80 and older hospitalized geriatric ward in the department and with anticoagulant.

Official Title
-----------------
Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?

Conditions
-----------------
Atrial Fibrillation, Gerontology

Intervention / Treatment
-----------------
* Other: questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalisation in geriatric unit Atrial fibrillation treated by anticoagulant treatment (AVK or oral anticoagulation) signed inform consent Exclusion Criteria: estimated lifetime less than 6 months under guardianship or curatorship without support person

Ages Eligible for Study
-----------------
Minimum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with atrial fibrillation with anticoagulant treatment<br> | Other: questionnaires<br>* scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| scale : HEMORR2HAGES | hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent... | at baseline | 
| scale : HAS-Bled | arterial hypertension, renal function, liver function, cerebrovascular accident... | at baseline | 
| scale : ATRIA | anemia, serious kidney diseases, hypertension, antecedent... | at baseline | 
| scale : shireman | gender, age, hemorrhage, diabetes, anemia... | at baseline | 
| scale charlson | age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer | at baseline | 
| scale : standardised geriatric assessment | comorbidities, cognition, mobility, pain, nutrition, living environment... | at baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of major bleeding event or not major |  | at baseline and 6 months | 
| genotyping | CYP2C9 | at baseline | 
| genotyping | VKCRC1 | at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anticoagulant